Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Nephrology · Hypertensive Nephrosclerosis

How High Blood Pressure and Genetics Affect Your Kidneys

At a Glance

Hypertensive nephrosclerosis is kidney damage linked to long-term high blood pressure, but it is not always caused by blood pressure alone. Inherited APOL1 variants, immune triggers, and other kidney diseases can affect risk and progression, so testing and biopsy decisions should be individualized.

When you are told your kidneys are failing because of high blood pressure, it is natural to feel a heavy sense of responsibility. You might wonder if you could have managed your stress better or started medication sooner. However, modern medicine shows that presumed hypertensive nephrosclerosis—the clinical pattern of kidney damage associated with high blood pressure—is far more complex than just a “pressure” problem. It is a biological process involving your blood vessels, your immune system, and often, your genetic blueprint [1][2].

How High Blood Pressure Damages the Kidneys

Your kidneys are filled with millions of tiny blood vessels and filters. When blood pressure remains high over a long period, it triggers a chain reaction of structural changes:

  1. Arteriolosclerosis (Vessel Hardening): To protect themselves from high pressure, the small arteries in your kidneys grow thicker and stiffer. While this “armors” the vessels, it also narrows the space inside them, reducing the vital flow of oxygen-rich blood to the rest of the kidney [3][4].
  2. Glomerulosclerosis (Filter Scarring): The kidney’s filters, called glomeruli, begin to struggle. Because the narrowed vessels can no longer regulate blood flow properly, the filters may be hit with bursts of high pressure or, conversely, may not get enough blood. This mechanical stress damages the podocytes—specialized cells that act as the kidney’s “gatekeepers.” Once these cells are lost, the filters develop scar tissue (sclerosis) and begin to leak protein into the urine [5][6].
  3. Tubulointerstitial Fibrosis (Deep Scarring): As the filters fail and blood flow drops, the surrounding kidney tissue becomes starved of oxygen. This leads to chronic inflammation and a deep type of scarring called fibrosis. This scarring is often the most accurate predictor of whether kidney disease will continue to progress [7][8].

The APOL1 Connection: Why Genetics Matter

For many people, especially those of recent African ancestry, the story of kidney disease may include a gene called APOL1. Thousands of years ago, certain variants of this gene (known as G1 and G2) evolved to protect people from “sleeping sickness,” a deadly disease caused by parasites in parts of Africa [9][10]. Today, however, carrying two of these “risk variants” increases the susceptibility to developing kidney disease [11].

It is vital to understand that having these gene variants does not guarantee you will get sick. Doctors describe this as incomplete penetrance, meaning the gene confers susceptibility, not an inevitable destiny [12][13].

The “Second Hit” Hypothesis

Most people with high-risk APOL1 genes never develop kidney failure. Researchers believe a “second hit”—an outside trigger—is usually needed to activate the gene’s harmful effects [14]. These triggers can include serious viral infections (such as HIV or COVID-19), significant inflammation from autoimmune diseases, or certain medications that stimulate the immune system [15][16][14]. However, these links remain context-dependent. You should never interpret this list as a reason to avoid vaccination, infection treatment, or medically necessary drugs without discussing them with your clinician.

Moving Past Guilt

The clinical label “hypertensive nephrosclerosis” can sometimes be misleading because it implies that blood pressure was the sole culprit. In reality, hypertension and kidney disease can cause each other, and they can coexist with other primary kidney diseases. Clinical studies of patients referred for a kidney biopsy because of atypical signs have shown that the initial clinical diagnosis is often incorrect when put to the test [2].

If you feel guilty about your diagnosis, remember:

  • Biology is not a choice: You cannot choose your genetic makeup or how your immune system responds to a virus [17].
  • A complex interplay: Your kidney health is determined by a mix of genetics, environment, and systemic health. High blood pressure is often just one piece of a much larger puzzle [1][18].
  • Focus on the future: While we cannot change the scarring that has already occurred, understanding these mechanisms helps your care team choose the right strategies to protect the kidney function you have left [17][19].

Should You Be Tested for APOL1?

Testing for APOL1 is a personal decision that should be made in consultation with your nephrologist and a genetic counselor. Current guidelines do not recommend testing for everyone, as the results generally do not change standard blood pressure or kidney-protective treatments today [17][20]. However, testing may be useful if:

  • You or a family member are considering donating a kidney (to inform the donor’s long-term risk assessment) [21][22].
  • Your kidney disease is unexplained or progressing in an atypical way [20].
  • You are interested in participating in clinical trials for new treatments specifically targeting the APOL1 pathway [17][23].

If you explore testing, a genetic counselor can help you navigate important topics like privacy, insurance implications, and how to communicate the findings with your family. Relatives should not be tested solely because one family member has an APOL1 risk variant.

Common questions in this guide

What is hypertensive nephrosclerosis, and does high blood pressure always cause it?
Hypertensive nephrosclerosis is a pattern of kidney damage associated with prolonged high blood pressure. High blood pressure may be one factor rather than the only cause, because genetic susceptibility, immune responses, and other kidney diseases can also contribute.
How does high blood pressure damage the kidneys?
Persistent high blood pressure can thicken and narrow the small blood vessels that supply the kidneys, reducing oxygen-rich blood flow. This can stress the kidney filters, cause protein to leak into the urine, and lead to deeper scarring that may contribute to disease progression.
What do APOL1 gene variants mean for kidney disease risk?
Having two high-risk APOL1 variants, called G1 or G2, can increase susceptibility to kidney disease, particularly in people with recent African ancestry, but it does not guarantee illness or kidney failure. Researchers think an additional trigger, such as a serious infection or significant inflammation, may be involved in some cases.
Should I have an APOL1 genetic test?
APOL1 testing is not routinely recommended for everyone because the result usually does not change standard blood pressure or kidney-protective treatment today. Testing may be worth discussing with a nephrologist and genetic counselor when kidney donation, unexplained or atypical disease, or a relevant clinical trial is being considered.
Can a kidney biopsy show that high blood pressure is not the only cause?
A kidney biopsy can help identify other kidney diseases when protein levels, the rate of kidney function decline, or other findings are atypical for hypertension-related damage. Whether a biopsy is appropriate depends on your medical history, test results, and the potential benefits and risks.
Is my kidney disease my fault if I had high blood pressure?
No. Kidney health reflects an interaction among blood pressure, genetics, the immune system, environment, and other health conditions, and kidney disease can also make blood pressure rise. Working with your care team can help protect the kidney function you have left.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my medical history and test results, how certain are you that hypertension is the primary cause of my kidney disease rather than a symptom of it?
  2. 2.Do my current protein levels or the rate of my kidney function decline suggest we should consider a biopsy to rule out other conditions?
  3. 3.Given my ancestry and family history, would APOL1 genetic testing provide useful information for my treatment plan or for my family members?
  4. 4.If I have a high-risk APOL1 genotype, what 'second hits' or triggers (like certain infections or medications) should I be particularly careful to avoid?
  5. 5.How do my blood pressure targets change now that we know my kidneys have been affected?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    The Role of Non-Coding RNA in the Pathogenesis of Hypertensive Nephropathy.

    Plewa P, Figiel K, Ćmil M, et al.

    Cells 2026; (15(8)) doi:10.3390/cells15080701.

    PMID: 42041569
  2. 2

    Hypertensive nephrosclerosis: wider kidney biopsy indications may be needed to improve diagnostics.

    Hallan SI, Øvrehus MA, Bjørneklett R, et al.

    Journal of internal medicine 2021; (289(1)):69-83 doi:10.1111/joim.13146.

    PMID: 32613703
  3. 3

    Heterogeneous afferent arteriolopathy: a key concept for understanding blood pressure-dependent renal damage.

    Kohagura K, Zamami R, Oshiro N, et al.

    Hypertension research : official journal of the Japanese Society of Hypertension 2024; (47(12)):3383-3396 doi:10.1038/s41440-024-01916-z.

    PMID: 39379463
  4. 4

    Molecular Mechanisms of Hypertensive Nephropathy: Renoprotective Effect of Losartan through Hsp70.

    Costantino VV, Gil Lorenzo AF, Bocanegra V, Vallés PG

    Cells 2021; (10(11)) doi:10.3390/cells10113146.

    PMID: 34831368
  5. 5

    Mesangial Injury and Capillary Ballooning Precede Podocyte Damage in Nephrosclerosis.

    Kriz W, Wiech T, Gröne HJ

    The American journal of pathology 2022; (192(12)):1670-1682 doi:10.1016/j.ajpath.2022.08.007.

    PMID: 36150506
  6. 6

    Roles of the mechanosensitive ion channel Piezo1 in the renal podocyte injury of experimental hypertensive nephropathy.

    Ogino S, Yoshikawa K, Nagase T, et al.

    Hypertension research : official journal of the Japanese Society of Hypertension 2024; (47(3)):747-759 doi:10.1038/s41440-023-01536-z.

    PMID: 38145990
  7. 7

    GPR97 deficiency ameliorates renal interstitial fibrosis in mouse hypertensive nephropathy.

    Wu JC, Wang XJ, Zhu JH, et al.

    Acta pharmacologica Sinica 2023; (44(6)):1206-1216 doi:10.1038/s41401-022-01041-y.

    PMID: 36635422
  8. 8

    Clinicopathological predictors for progression of chronic kidney disease in nephrosclerosis: a biopsy-based cohort study.

    Yamanouchi M, Hoshino J, Ubara Y, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2019; (34(7)):1182-1188 doi:10.1093/ndt/gfy121.

    PMID: 29788462
  9. 9

    APOL1 renal risk variants have contrasting resistance and susceptibility associations with African trypanosomiasis.

    Cooper A, Ilboudo H, Alibu VP, et al.

    eLife 2017; (6()).

    PMID: 28537557
  10. 10

    APOL1 and Kidney Disease: From Genetics to Biology.

    Friedman DJ, Pollak MR

    Annual review of physiology 2020; (82()):323-342 doi:10.1146/annurev-physiol-021119-034345.

    PMID: 31710572
  11. 11

    APOL1, Sickle Cell Trait, and CKD in the Jackson Heart Study.

    Young BA, Wilson JG, Reiner A, et al.

    Kidney medicine 2021; (3(6)):962-973.e1 doi:10.1016/j.xkme.2021.05.004.

    PMID: 34939005
  12. 12

    Recessive, gain-of-function toxicity in an APOL1 BAC transgenic mouse model mirrors human APOL1 kidney disease.

    McCarthy GM, Blasio A, Donovan OG, et al.

    Disease models & mechanisms 2021; (14(8)) doi:10.1242/dmm.048952.

    PMID: 34350953
  13. 13

    Genetic Inhibition of APOL1 Pore-Forming Function Prevents APOL1-Mediated Kidney Disease.

    Hung AM, Assimon VA, Chen HC, et al.

    Journal of the American Society of Nephrology : JASN 2023; (34(11)):1889-1899 doi:10.1681/ASN.0000000000000219.

    PMID: 37798822
  14. 14

    APOL1-Associated Collapsing Focal Segmental Glomerulosclerosis in a Patient With Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset in Infancy (SAVI).

    Abid Q, Best Rocha A, Larsen CP, et al.

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2020; (75(2)):287-290 doi:10.1053/j.ajkd.2019.07.010.

    PMID: 31601430
  15. 15

    APOL1 Risk Variants, Acute Kidney Injury, and Death in Participants With African Ancestry Hospitalized With COVID-19 From the Million Veteran Program.

    Hung AM, Shah SC, Bick AG, et al.

    JAMA internal medicine 2022; (182(4)):386-395 doi:10.1001/jamainternmed.2021.8538.

    PMID: 35089317
  16. 16

    Donor's APOL1 Risk Genotype and "Second Hits" Associated With De Novo Collapsing Glomerulopathy in Deceased Donor Kidney Transplant Recipients: A Report of 5 Cases.

    Chang JH, Husain SA, Santoriello D, et al.

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2019; (73(1)):134-139 doi:10.1053/j.ajkd.2018.05.008.

    PMID: 30054024
  17. 17

    APOL1 kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

    Ojo AO, Adu D, Bramham K, et al.

    Kidney international 2025; (108(5)):763-779 doi:10.1016/j.kint.2025.05.017.

    PMID: 40582702
  18. 18

    Vascular injury in glomerulopathies: the role of the endothelium.

    Barbosa GSB, Câmara NOS, Ledesma FL, et al.

    Frontiers in nephrology 2024; (4()):1396588 doi:10.3389/fneph.2024.1396588.

    PMID: 39780910
  19. 19

    APOL1 testing in clinical practice and opportunities for new therapies.

    Lee T, Ma L, Freedman BI

    Current opinion in nephrology and hypertension 2025; (34(6)):500-506 doi:10.1097/MNH.0000000000001082.

    PMID: 40314119
  20. 20

    Diagnosis, Education, and Care of Patients with APOL1-Associated Nephropathy: A Delphi Consensus and Systematic Review.

    Freedman BI, Burke W, Divers J, et al.

    Journal of the American Society of Nephrology : JASN 2021; (32(7)):1765-1778 doi:10.1681/ASN.2020101399.

    PMID: 33853887
  21. 21

    Practical Considerations for APOL1 Genotyping in the Living Kidney Donor Evaluation.

    Mena-Gutierrez AM, Reeves-Daniel AM, Jay CL, Freedman BI

    Transplantation 2020; (104(1)):27-32 doi:10.1097/TP.0000000000002933.

    PMID: 31449181
  22. 22

    Evaluating ApoL1 Genetic Testing Policy Options for Transplant Centers: A Delphi Consensus Panel Project with Stakeholders.

    McIntosh T, Walsh H, Baldwin K, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2024; (19(4)):494-502 doi:10.2215/CJN.0000000000000397.

    PMID: 38190141
  23. 23

    Design and Rationale of the Phase 2 Baricitinib Study in Apolipoprotein L1-Mediated Kidney Disease (JUSTICE).

    Olabisi OA, Barrett NJ, Lucas A, et al.

    Kidney international reports 2024; (9(9)):2677-2684 doi:10.1016/j.ekir.2024.06.033.

    PMID: 39291185

This page is for informational purposes only and does not constitute medical advice about nephrosclerosis, APOL1 testing, or blood pressure care. Discuss your personal risks and treatment decisions with your nephrologist and, when appropriate, a genetic counselor.

Get notified when new evidence is published on nephrosclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.